Literature DB >> 14500668

Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs.

Fernanda Elias1, Juan Flo, Ricardo A Lopez, Jorge Zorzopulos, Alejandro Montaner, Juan M Rodriguez.   

Abstract

Synthetic oligodeoxynucleotides (ODNs) containing cytosine-guanosine (CpG) motifs stimulate B and plasmacytoid dendritic cells of the vertebrate immune system. We found that in primates strong stimulation of these cells could also be achieved using certain non-CpG ODNs. The immunostimulatory motif in this case is a sequence with the general formula PyNTTTTGT in which Py is C or T, and N is A, T, C, or G. Assays performed on purified cells indicated that the immunostimulatory activity is direct. The use of a nuclease-resistant phosphorothioate backbone is not a necessary condition, since phosphodiester PyNTTTTGT ODNs are active. It was also demonstrated that ODN 2006, a widely used immunostimulant of human B cells, possess two kinds of immunostimulatory motifs: one of them mainly composed of two successive TCG trinucleotides located at the 5' end and another one (duplicated) of the PyNTTTTGT kind here described. Even though PyNTTTTGT ODNs are mainly active on primate cells, some of them, bearing the CATTTTGT motif, have a small effect on cells from other mammals. This suggests that the immunostimulatory mechanism activated by these ODNs was present before, but optimized during, evolution of primates. Significant differences in the frequency of PyNTTTTGT sequences between bacterial and human DNA were not found. Thus, the possibility that PyNTTTTGT ODNs represent a class of pathogen-associated molecular pattern is unlikely. They could, more reasonably, be included within the category of danger signals of cell injury.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14500668     DOI: 10.4049/jimmunol.171.7.3697

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.

Authors:  Jörg Vollmer; Risini D Weeratna; Marion Jurk; Ulrike Samulowitz; Michael J McCluskie; Paul Payette; Heather L Davis; Christian Schetter; Arthur M Krieg
Journal:  Immunology       Date:  2004-10       Impact factor: 7.397

Review 2.  Plasmacytoid dendritic cells: linking innate and adaptive immunity.

Authors:  Kelli McKenna; Anne-Sophie Beignon; Nina Bhardwaj
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Structural and functional characterisation of the Toll like receptor 9 of Aotus nancymaae, a non-human primate model for malaria vaccine development.

Authors:  Rolf Spirig; Elisabetta Peduzzi; Manuel E Patarroyo; Gerd Pluschke; Claudia A Daubenberger
Journal:  Immunogenetics       Date:  2005-04-08       Impact factor: 2.846

4.  Oligodeoxynucleotide IMT504 induces a marked recovery in a streptozotocin-induced model of diabetes in rats: correlation with an early increase in the expression of nestin and neurogenin 3 progenitor cell markers.

Authors:  M S Bianchi; A Hernando-Insúa; N A Chasseing; J M Rodríguez; F Elías; N Lago; J Zorzopulos; C Libertun; A D Montaner; V A Lux-Lantos
Journal:  Diabetologia       Date:  2010-03-11       Impact factor: 10.122

5.  Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions.

Authors:  Anne-Sophie Beignon; Kelli McKenna; Mojca Skoberne; Olivier Manches; Ida DaSilva; Daniel G Kavanagh; Marie Larsson; Robert J Gorelick; Jeffrey D Lifson; Nina Bhardwaj
Journal:  J Clin Invest       Date:  2005-10-13       Impact factor: 14.808

6.  The novel immunotherapeutic oligodeoxynucleotide IMT504 protects neutropenic animals from fatal Pseudomonas aeruginosa bacteremia and sepsis.

Authors:  Abdullah Chahin; Steven M Opal; Jorge Zorzopulos; David V Jobes; Yazan Migdady; Michelle Yamamoto; Nicholas Parejo; John E Palardy; David L Horn
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

7.  Requirement for DNA CpG content in TLR9-dependent dendritic cell activation induced by DNA-containing immune complexes.

Authors:  Kei Yasuda; Christophe Richez; Melissa B Uccellini; Rocco J Richards; Ramon G Bonegio; Shizuo Akira; Marc Monestier; Ronald B Corley; Gregory A Viglianti; Ann Marshak-Rothstein; Ian R Rifkin
Journal:  J Immunol       Date:  2009-07-31       Impact factor: 5.422

8.  Non-clinical safety studies of IMT504, a unique non-CpG oligonucleotide.

Authors:  Raúl Franco; Juan M Rodriguez; Fernanda Elías; Andrés Hernando-Insúa; Juan Fló; Ricardo López; Carlos Nagle; Néstor Lago; Jorge Zorzopulos; David L Horn; Alejandro D Montaner
Journal:  Nucleic Acid Ther       Date:  2014-04-10       Impact factor: 5.486

9.  Autoreactive B cells discriminate CpG-rich and CpG-poor DNA and this response is modulated by IFN-alpha.

Authors:  Melissa B Uccellini; Liliana Busconi; Nathaniel M Green; Patricia Busto; Sean R Christensen; Mark J Shlomchik; Ann Marshak-Rothstein; Gregory A Viglianti
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

10.  IMT504 Provides Analgesia by Modulating Cell Infiltrate and Inflammatory Milieu in a Chronic Pain Model.

Authors:  Candelaria Leiguarda; Constanza Potilinski; Julia Rubione; Pablo Tate; Marcelo J Villar; Alejandro Montaner; Verónica Bisagno; Luis Constandil; Pablo R Brumovsky
Journal:  J Neuroimmune Pharmacol       Date:  2020-11-21       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.